PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23158401-1 2013 To obtain a thrombin generation (TG) curve from the conversion of added fluorogenic substrate, thrombin concentrations are to be derived from the observed velocity of increase of fluorescence (dF/dt). Thymidine 196-198 coagulation factor II, thrombin Homo sapiens 95-103 22300379-5 2012 The length of the thymidine linkers and TBA density on Au NPs surfaces have strong impact on the orientation, flexibility, and stability of MP-TBA(15)/TBA(29)-Tn-Au NPs, leading to their stronger binding strength with thrombin. Thymidine 18-27 coagulation factor II, thrombin Homo sapiens 218-226 22300379-7 2012 42 TBA(15) and 42 TBA(29) molecules per Au NP; 15-mer thymidine on aptamer terminal) provided the highest binding affinity toward thrombin with a dissociation constant of 5.2 x 10(-11) M. As a result, they had 8 times higher anticoagulant (inhibitory) potency relative to TBA(15)/TBA(29)-T(15)-Au NPs (prepared in the absence of thrombin). Thymidine 54-63 coagulation factor II, thrombin Homo sapiens 130-138 18752966-2 2008 A series of modified thrombin binding aptamers (TBAs) in which the new acyclic nucleoside replaces, one at the time, the thymidine residues were then synthesized and characterized by UV, CD, MS, and (1)H NMR. Thymidine 121-130 coagulation factor II, thrombin Homo sapiens 21-29 26616765-4 2010 Our present understanding suggests either the 15-TBA single stranded loops containing sequential thymidines (TT) or alternatively a single-stranded loop, containing a guanine flanked by 2 thymidines (TGT), physically associates with thrombin protein. Thymidine 97-107 coagulation factor II, thrombin Homo sapiens 233-241 18989937-2 2008 The results, using thrombin as the model system, showed that as the number of thymidine (T) units in the linker increases from 0 to 20 in four separate increments (T(0), T(5), T(10), T(20)), the surface density of the aptamer decreased linearly from approximately 25 to 12 pmol x cm(-2). Thymidine 78-87 coagulation factor II, thrombin Homo sapiens 19-27 18989937-4 2008 In addition, thrombin binding capacity was shown to increase as the linker length increased from 0 to 5 thymidine nucleotides and then decreased as the number of thymidine residues increased to 20 due to a balance between two different effects. Thymidine 104-113 coagulation factor II, thrombin Homo sapiens 13-21 15656605-2 2005 One caged thymidine in a key location is enough to completely mask the aptamer"s function in respect to their affinity for thrombin and their inhibition of the blood clotting cascade. Thymidine 10-19 coagulation factor II, thrombin Homo sapiens 123-131 15728549-8 2005 Repeated exposure to thrombin produced a significant increase in cell coverage in the capsular bag model and increased [(3)H]thymidine incorporation into FHL124 cells. Thymidine 125-134 coagulation factor II, thrombin Homo sapiens 21-29 14871182-7 2004 Measurement of 3[H]-thymidine incorporation revealed a dose-dependent increase of DNA synthesis in response to thrombin treatment. Thymidine 20-29 coagulation factor II, thrombin Homo sapiens 111-119 15229942-4 2004 The effect of thrombin on the proliferation of synovial fibroblast-like cells (SFC) was examined by measuring 3H-thymidine incorporation. Thymidine 113-122 coagulation factor II, thrombin Homo sapiens 14-22 11336112-6 2001 In the present study we demonstrate that this peptide inhibited only thrombin- and tethered ligand-induced human vascular smooth muscle cell proliferation as determined by (3H)-thymidine incorporation and has no effect on platelet-derived growth factor and serum-induced smooth muscle cell proliferation. Thymidine 177-186 coagulation factor II, thrombin Homo sapiens 69-77 11812655-3 2002 In this study, thrombin stimulated [3H]thymidine incorporation and p42/p44 mitogen-activated protein kinase (MAPK) phosphorylation in a time- and concentration-dependent manner in TSMCs. Thymidine 39-48 coagulation factor II, thrombin Homo sapiens 15-23 11306243-7 2001 In addition, thrombin-induced [3H]-thymidine incorporation and p42/p44 MAPK phosphorylation was completely inhibited by PD98059 (an inhibitor of MEK1/2), indicating that activation of MEK1/2 was required for these responses. Thymidine 35-44 coagulation factor II, thrombin Homo sapiens 13-21 10820165-8 2000 Thrombin induced a significant and dose-dependent increase in thymidine uptake and a striking upregulation of MCP-1 mRNA expression and protein release into the supernatant. Thymidine 62-71 coagulation factor II, thrombin Homo sapiens 0-8 11020444-12 2000 Thrombin- and TK-stimulated [(3)H]thymidine incorporation also was inhibited completely by SCH 79797. Thymidine 34-43 coagulation factor II, thrombin Homo sapiens 0-8 11231371-7 2001 RESULTS: The thrombin-activated platelet supernatant from hemodialysis patients (N = 15) increased the [(3)H]-thymidine incorporation rate in VSMC s in comparison to the supernatant of healthy control subjects (N = 17, counts/supernatant of 10(6) stimulated platelets +/- SEM, 604 +/- 71 vs. 364 +/- 45, P < 0.05). Thymidine 110-119 coagulation factor II, thrombin Homo sapiens 13-21 9107175-9 1997 In SMCs thrombin induced more pronounced [3H]thymidine incorporation (inhibited by r-hirudin or PPACK) in SV than IMA (P < .05), but activation of p42MAPK was similar in both vessels. Thymidine 45-54 coagulation factor II, thrombin Homo sapiens 8-16 9179374-14 1997 Addition of salbutamol (100 nM) at different times either before or up to 24 h after the addition of thrombin indicated that [3H]-thymidine incorporation (measured between 24 and 28 h after thrombin) could be significantly attenuated when salbutamol was added as late as 18 h after the addition of thrombin. Thymidine 130-139 coagulation factor II, thrombin Homo sapiens 101-109 9179374-14 1997 Addition of salbutamol (100 nM) at different times either before or up to 24 h after the addition of thrombin indicated that [3H]-thymidine incorporation (measured between 24 and 28 h after thrombin) could be significantly attenuated when salbutamol was added as late as 18 h after the addition of thrombin. Thymidine 130-139 coagulation factor II, thrombin Homo sapiens 190-198 9179374-14 1997 Addition of salbutamol (100 nM) at different times either before or up to 24 h after the addition of thrombin indicated that [3H]-thymidine incorporation (measured between 24 and 28 h after thrombin) could be significantly attenuated when salbutamol was added as late as 18 h after the addition of thrombin. Thymidine 130-139 coagulation factor II, thrombin Homo sapiens 190-198 10622485-5 1999 Thrombin, at and above 1 U/mL, stimulated the rate of thymidine incorporation into hOBs. Thymidine 54-63 coagulation factor II, thrombin Homo sapiens 0-8 10622485-7 1999 A synthetic peptide ligand for the thrombin receptor enhanced the rate of [3H]thymidine incorporation in hOBs, indicating that thrombin-induced proliferation is mediated via the tetheric thrombin receptor. Thymidine 78-87 coagulation factor II, thrombin Homo sapiens 35-43 10622485-7 1999 A synthetic peptide ligand for the thrombin receptor enhanced the rate of [3H]thymidine incorporation in hOBs, indicating that thrombin-induced proliferation is mediated via the tetheric thrombin receptor. Thymidine 78-87 coagulation factor II, thrombin Homo sapiens 127-135 10622485-7 1999 A synthetic peptide ligand for the thrombin receptor enhanced the rate of [3H]thymidine incorporation in hOBs, indicating that thrombin-induced proliferation is mediated via the tetheric thrombin receptor. Thymidine 78-87 coagulation factor II, thrombin Homo sapiens 127-135 10484455-4 1999 Significant enhancement of [(3)H]thymidine incorporation in HASM cultures was observed only by treatment with agents (epidermal growth factor, platelet-derived growth factor, thrombin, and phorbol 12-myristate 13-acetate) that promoted a strong and sustained activation of p42/p44 MAPK. Thymidine 33-42 coagulation factor II, thrombin Homo sapiens 175-183 10381504-7 1999 Epo-, SCF-, and PMA-induced thymidine incorporation was potently inhibited by thrombin (half-maximal inhibition with 0.1 U/mL). Thymidine 28-37 coagulation factor II, thrombin Homo sapiens 78-86 9615911-7 1998 Human SMC response ([3H]-thymidine incorporation) to either sera or thrombin was lower than that of porcine cells. Thymidine 25-34 coagulation factor II, thrombin Homo sapiens 68-76 9615911-9 1998 In human cells, thrombin elicited an overexpression of c-fos and a lower rate of [3H]-thymidine incorporation than in porcine cells. Thymidine 86-95 coagulation factor II, thrombin Homo sapiens 16-24 8174632-2 1994 Addition of serum or thrombin stimulates incorporation of 3H-labeled thymidine 16-40 h later. Thymidine 69-78 coagulation factor II, thrombin Homo sapiens 21-29 9105886-8 1997 The effect of thrombin, TRAP-14 and A6Y on [3H]thymidine incorporation into DNA was significantly prevented by L9R, a 9-amino-acid peptide (Leu-Val-Arg-D-Cys-Gly-Lys-His-Ser-Arg; IC50 = 180 microM against thrombin and TRAP-14 and 800 microM against A6Y) previously described as an antagonist in human platelet aggregation. Thymidine 47-56 coagulation factor II, thrombin Homo sapiens 14-22 9105886-8 1997 The effect of thrombin, TRAP-14 and A6Y on [3H]thymidine incorporation into DNA was significantly prevented by L9R, a 9-amino-acid peptide (Leu-Val-Arg-D-Cys-Gly-Lys-His-Ser-Arg; IC50 = 180 microM against thrombin and TRAP-14 and 800 microM against A6Y) previously described as an antagonist in human platelet aggregation. Thymidine 47-56 coagulation factor II, thrombin Homo sapiens 205-213 8903003-5 1996 Exogenously added thrombin increased thymidine incorporation into HUVSMC to 240 +/- 30% of basal (EC50 = 0.49 +/- 0.09 nM) and thrombin inhibitors blocked this effect (IC50 = 10 +/- 3, 37 +/- 17, 343 +/- 165 and 1402 +/- 758 nM for rec-hirudin, hirunorm, Napap and hirulog-1, respectively). Thymidine 37-46 coagulation factor II, thrombin Homo sapiens 18-26 8719799-5 1995 Pretreatment of smooth muscle cells with dexamethasone (100 nM, 60 min) inhibited thrombin-induced increases in [3H]-thymidine incorporation (DNA synthesis) and cell number. Thymidine 117-126 coagulation factor II, thrombin Homo sapiens 82-90 8719799-7 1995 Inhibition of thrombin-induced [3H]-thymidine incorporation was also observed with hydrocortisone (0.01-1 microM) and methylprednisolone (0.001-0.1 microM) pretreatment. Thymidine 36-45 coagulation factor II, thrombin Homo sapiens 14-22 8719799-14 1995 The potency of hydrocortisone as an inhibitor of [3H]-thymidine incorporation was reduced when FCS (10% v/v, which caused a 40 fold increase in [3H]-thymidine incorporation) was used as the mitogen in place of thrombin (0.3 u ml-1, which caused a 10 fold increase in [3H]-thymidine incorporation). Thymidine 54-63 coagulation factor II, thrombin Homo sapiens 210-218 7657283-3 1995 Thrombin stimulated DNA synthesis and proliferation of FSC, as assessed by [3H]-thymidine incorporation assay and measurement of cell number, respectively. Thymidine 80-89 coagulation factor II, thrombin Homo sapiens 0-8 7657283-11 1995 TRAP mimicked the effects of thrombin on [3H]-thymidine incorporation, MCP-1 secretion, and MCP-1 gene expression. Thymidine 46-55 coagulation factor II, thrombin Homo sapiens 29-37 7605251-7 1995 Thrombin dose-dependently enhanced the incorporation of [3H]-thymidine into DNA in pulpal fibroblasts by a mechanism that was unrelated to the effect on prostanoid biosynthesis. Thymidine 56-70 coagulation factor II, thrombin Homo sapiens 0-8 8365478-6 1993 Both alpha-thrombin (0.01 to 0.15 U/ml) and TSP (5 to 600 ng/ml) caused a dose-dependent increase in [3H]thymidine incorporation by MG-63 cells. Thymidine 105-114 coagulation factor II, thrombin Homo sapiens 11-19 1486937-7 1992 Incorporation of thymidine into DNA in confluent cultures was also stimulated by thrombin, with a four-fold increase in incorporation at 35 hr in thrombin-treated cells compared to controls. Thymidine 17-26 coagulation factor II, thrombin Homo sapiens 81-89 1334075-9 1992 Thrombin and Tg release 30 and 70% (respectively) of the DT Ca2+ available at any instant, independent of order of challenge, consistent with a single class of DT with respect to these agents. Thymidine 57-59 coagulation factor II, thrombin Homo sapiens 0-8 1334075-9 1992 Thrombin and Tg release 30 and 70% (respectively) of the DT Ca2+ available at any instant, independent of order of challenge, consistent with a single class of DT with respect to these agents. Thymidine 160-162 coagulation factor II, thrombin Homo sapiens 0-8 1486937-7 1992 Incorporation of thymidine into DNA in confluent cultures was also stimulated by thrombin, with a four-fold increase in incorporation at 35 hr in thrombin-treated cells compared to controls. Thymidine 17-26 coagulation factor II, thrombin Homo sapiens 146-154 1963793-1 1990 Esterolytically inactive diisopropyl fluorophosphate-conjugated thrombin (DIP-alpha-thrombin) stimulated 3H-thymidine incorporation and proliferation of growth-arrested vascular smooth muscle cells (SMCs), similar to native alpha-thrombin. Thymidine 108-117 coagulation factor II, thrombin Homo sapiens 64-72 1963793-1 1990 Esterolytically inactive diisopropyl fluorophosphate-conjugated thrombin (DIP-alpha-thrombin) stimulated 3H-thymidine incorporation and proliferation of growth-arrested vascular smooth muscle cells (SMCs), similar to native alpha-thrombin. Thymidine 108-117 coagulation factor II, thrombin Homo sapiens 84-92 1963793-1 1990 Esterolytically inactive diisopropyl fluorophosphate-conjugated thrombin (DIP-alpha-thrombin) stimulated 3H-thymidine incorporation and proliferation of growth-arrested vascular smooth muscle cells (SMCs), similar to native alpha-thrombin. Thymidine 108-117 coagulation factor II, thrombin Homo sapiens 84-92 35409180-4 2022 In this paper, we report the preparation of designer thrombin aptamer OPCs with peptide side chains anchored to a particular thymidine residue of the aptamer. Thymidine 125-134 coagulation factor II, thrombin Homo sapiens 53-61 2153536-5 1990 Thrombin produced a dose-dependent increase in intracellular free calcium (Cai2+) in UMR 106-H5 cells (EC50 1 U/ml; maximal increase 4-fold), as well as a small (20%) increase in [3H]thymidine incorporation. Thymidine 183-192 coagulation factor II, thrombin Homo sapiens 0-8 6111398-10 1981 Furthermore, pretreatment of cultures with taxol (5 micrograms/ml) inhibited approximately 30% of the stimulation of thymidine incorporation by thrombin. Thymidine 117-126 coagulation factor II, thrombin Homo sapiens 144-152 3718412-1 1986 In tumor cell thrombosis thrombin does not only act as clotting enzyme but also as tissue hormone stimulating the proliferation of malignant cells indicated by an increase of cell count and thymidine uptake in cell cultures. Thymidine 190-199 coagulation factor II, thrombin Homo sapiens 25-33 6339667-5 1983 Secretion products from human platelets after their aggregation by thrombin stimulated [3H]thymidine uptake at a concentration of 2% (v/v), but were inhibitory at high concentrations. Thymidine 91-100 coagulation factor II, thrombin Homo sapiens 67-75 140878-1 1977 Incubation of primary human fibroblasts in serum-free medium with small concentrations of thrombin, trypsin or plasmin resulted in manyfold increase in total DNA synthesis and in the number of 3H-thymidine labelled cells. Thymidine 196-205 coagulation factor II, thrombin Homo sapiens 90-98 31956796-0 2020 Methoxymethyl Threofuranosyl Thymidine (4"-MOM-TNA-T) at the T7 Position of the Thrombin-Binding Aptamer Boosts Anticoagulation Activity, Thermal Stability, and Nuclease Resistance. Thymidine 0-38 coagulation factor II, thrombin Homo sapiens 80-88 33156614-4 2020 TBA folds into an antiparallel G-quadruplex (GQ) with loop thymidine (T) residues interacting directly with the protein in the thrombin-TBA complex. Thymidine 59-68 coagulation factor II, thrombin Homo sapiens 127-135 31956796-1 2020 The synthesis of 4"-methoxymethyl threofuranosyl (4"-MOM-TNA) thymidine and derived oligomers of the G-rich thrombin-binding aptameric (TBA) sequence is reported. Thymidine 62-71 coagulation factor II, thrombin Homo sapiens 108-116 29458015-10 2018 Additionally, ortho-nitro-benzenesulfonamide at concentrations of 1.5 mumol/mL was found to significantly decrease reaction velocity ( dA/dt) in the thrombin activity assay. Thymidine 139-141 coagulation factor II, thrombin Homo sapiens 150-158